VYNE Therapeutics (VYNE) Receivables - Net (2017 - 2023)

VYNE Therapeutics' Receivables - Net history runs 7 years deep, the most recent figure standing at $250000.0 for Q3 2023.

• Quarterly Receivables - Net fell 46.92% year-over-year to $250000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $250000.0 (down 46.92% YoY) and the FY2022 annual result came in at $173000.0, down 97.72% from the prior year.
• Receivables - Net was $250000.0 for Q3 2023 at VYNE Therapeutics, up from $234000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $15.8 million in Q4 2020 and bottomed at $105000.0 in Q1 2023.
• A 5-year average of $5.2 million and a median of $3.5 million in 2020 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2020 — Receivables - Net jumped 11617.78% — and 2022, when it slumped 97.72%.
• VYNE Therapeutics' Receivables - Net stood at $135000.0 in 2019, then soared by 11617.78% to $15.8 million in 2020, then plunged by 52.06% to $7.6 million in 2021, then slumped by 97.72% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
• Business Quant data shows VYNE's Receivables - Net at $250000.0 in Q3 2023, $234000.0 in Q2 2023, and $105000.0 in Q1 2023.